Company / Free Cash Flow
CytomX Therapeutics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$75.8M
FY2025
5-year range
-$120.6M / -$56.9M
FY2021-FY2025
Trend
+12.4%
vs FY2024
Sector context
#96 of 194
Health Care
What the data says
At -$76M, CytomX Therapeutics, Inc.'s free cash flow ranks #96 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 10 years, ranging from -$144M in FY2019 to $169M in FY2017.
Based on SEC 10-K filings.
-$76M in FY2025.
Declined from -$57M to -$76M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#96 of 194 in Health CareTop 49% of 194This company -$75.8M Sector average $470.6M
▼
-116.1% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 12.4% year-over-year.
- Ranks #96 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2017.
- Lowest free cash flow in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$75.8M | +12.4% |
| FY2024 | -$86.5M | -52.2% |
| FY2023 | -$56.9M | +49.5% |
| FY2022 | -$112.5M | +6.7% |
| FY2021 | -$120.6M | -4189.5% |
| FY2020 | $3.0M | +102.0% |
| FY2019 | -$144.0M | -81.5% |
| FY2018 | -$79.3M | -147.0% |
| FY2017 | $168.8M | +4111.7% |
| FY2016 | -$4.2M | +51.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026